Diaceutics, the diagnostics data analytics and implementation services company, has today announced a significant new contract deal - worth $1.27m - with a leading pharmaceutical company.
Diaceutics said it will collaborate with the new client to produce an outsourced commercial solution for its US market, using its new DXRX platform to improve patient testing and support it activities in the field of immunotherapy.
Its technology will help the pharma company to ensure seamless diagnostic testing for their new precision medicine drugs, which will allow them to increase the number of patients getting access to potentially life-saving treatments.
Peter Keeling, the company's chief executive, said the client win marks another milestone in the commercial success of Diaceutics.
"Our data and new commercialisation platform DXRX are designed to provide a full end-to-end service, and via these we believe we are well placed to significantly improve patient testing for our clients' therapy in this challenging cancer setting," Mr Keeling added.
